A Prospective Randomized Clinical Trial of Platelet-Rich Plasma Used in Surgery for De Quervain Tendinopathy
Hui Lu,LiFeng Chen,Qiang Chen,Hui Shen,Shuai Jiang,Hang Yu
DOI: https://doi.org/10.1166/jbt.2017.1703
2017-01-01
Journal of Biomaterials and Tissue Engineering
Abstract:Background: Platelet-rich plasma (PRP) is used for healing tendon and bone by the concentration of growth factors. We try to implement this technology for de Quervain tendinopathy, and to evaluate its clinical efficacy. Method: This was a prospective randomized study of 52 patients operated for de Quervain tendinopathy. Patients were randomly allocated to combined-therapy group (surgery plus PRP, n = 26) or control group (surgery only, n = 26). All patients were evaluated by The Patientrated Wrist Evaluation (PRWE) before and at 3, 6, 12 months after the operation. Result: One patient of the combined-therapy group was lost to follow-up, 51 patients (combined-therapy group n = 25, control group n = 26) completed the study. The average age was 47.608 +/- 13.242 years old (range 21-71). 2 of 25 (8%) patients in the combined-therapy group and 3 of 26 (13%) patients in the control group had complications such as local infection or superficial radial nerve injury. No evidence of tendon rupture and volar subluxation of tendons were found. There were significant differences between the preoperative PRWE score (51.580 +/- 8.093) and each of the post-operative PRWE scores of three months (28.640 +/- 4.424, p< 0.0001, t = 18.76), six months (14.220 +/- 2.479, p< 0.0001, t = 24.43) and 12 months (10.520 +/- 2.489, p< 0.0001, t = 27.45) after operation in the combined-therapy group. There were significant differences between the preoperative PRWE score (52.788 +/- 6.073) and each of the post-operative PRWE scores of three months (23.058 +/- 5.156, p< 0.0001, t = 29.35), six months (18.135 +/- 3.799, p< 0.0001, t = 42.64) and 12 months (18.923 +/- 3.489, p < 0.0001, t = 46.46) after operation in the control group. All patients in two groups had an obvious improvement of pain and function. The PRWE score at three months after operation in the combined-therapy group was higher than that of the control group at three months after operation (p< 0.0001, t = 4.432), but PRWE scores at six months and 12 months after operation in the combined-therapy group were lower than those of the control group at six months (p < 0.0001, t = 2.860) and 12 months (p < 0.0001, t = 5.971) after operation. These results demonstrated that combined-therapy group had a better improvement than control group at six months and 12 months after operation. There was no significant difference of PRWE scores in control group between six months and 12 months after operation (p = 0.1101, t = 1.657). Conclusion: Compared with the control group, Platelet-Rich Plasma may be more effective for de Quervain tendinopathy during the late follow-up (after 6 months). Further study of PRP treatment is warranted. This should include a longer duration of follow-up and a larger sample size.